Tysabri Approved By NICE, UK

Main Category: Multiple Sclerosis
Article Date: 28 Aug 2007 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The MS Society has welcomed the decision, which will benefit nearly 3,000 people with this form of MS.

Simon Gillespie, chief executive of the MS Society, said: "We welcome confirmation of NICE's decision to approve Tysabri, which represents a vital treatment option for people with highly active relapsing remitting MS.

"The health trusts now have three months to make Tysabri available and we hope there are no unnecessary delays.

Simon added: "We will be keeping a close eye on prescribing to make sure that people who stand to benefit from Tysabri are able to get the drug locally and we hope no-one finds their access limited by local funding concerns."

The Scottish Medicines Consortium is currently revising its initial decision to reject funding for Tysabri. A decision is due in September.

http://www.mssociety.org.uk